BRVO | CRVO | |||||
---|---|---|---|---|---|---|
Improvement or worsening at month 1 | Ranibizumab (n1 = 131) | Sham (n2 = 132) | Relative risk (95% CI)‡ | Ranibizumab (n1 = 130) | Sham (n2 = 130) | Relative risk (95% CI)‡ |
Gain ≥ 20 letters | 0.191 | 0.038 | 5.04 (1.99, 12.76) | 0.131 | 0.031 | 4.25 (1.47, 12.29) |
Gain ≥ 10 letters and <20 letters | 0.313 | 0.197 | 1.59 (1.04, 2.44) | 0.331 | 0.100 | 3.31 (1.87, 5.85) |
Loss <10 letters and gain <10 letters | 0.489 | 0.705 | 0.69 (0.56, 0.85) | 0.523 | 0.762 | 0.69 (0.57, 0.83) |
Loss ≥10 letters and <20 letters | 0.008 | 0.045 | 0.17 (0.02, 1.38) | 0.015 | 0.077 | 0.20 (0.04, 0.90) |
Loss ≥20 letters | 0.000 | 0.015 | 0.00 (0.00, 0.00) | 0.000 | 0.031 | 0.00 (0.00, 0.00) |